OA11648A - 4,4-Biarylpiperidine derivatives with opioid receptor activity. - Google Patents

4,4-Biarylpiperidine derivatives with opioid receptor activity. Download PDF

Info

Publication number
OA11648A
OA11648A OA1200100057A OA1200100057A OA11648A OA 11648 A OA11648 A OA 11648A OA 1200100057 A OA1200100057 A OA 1200100057A OA 1200100057 A OA1200100057 A OA 1200100057A OA 11648 A OA11648 A OA 11648A
Authority
OA
OAPI
Prior art keywords
comp
phenyl
alkyl
formula
piperidin
Prior art date
Application number
OA1200100057A
Other languages
English (en)
Inventor
Spiros Liras
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11648A publication Critical patent/OA11648A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
OA1200100057A 1998-09-09 1999-09-06 4,4-Biarylpiperidine derivatives with opioid receptor activity. OA11648A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9956598P 1998-09-09 1998-09-09

Publications (1)

Publication Number Publication Date
OA11648A true OA11648A (en) 2004-12-08

Family

ID=22275622

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100057A OA11648A (en) 1998-09-09 1999-09-06 4,4-Biarylpiperidine derivatives with opioid receptor activity.

Country Status (41)

Country Link
US (2) US6720336B2 (es)
EP (1) EP1112255B1 (es)
JP (1) JP2002524445A (es)
KR (1) KR20010075024A (es)
CN (1) CN1316993A (es)
AP (1) AP2001002088A0 (es)
AR (1) AR022376A1 (es)
AT (1) ATE312819T1 (es)
AU (1) AU749096B2 (es)
BG (1) BG105411A (es)
BR (1) BR9913512A (es)
CA (1) CA2343236C (es)
CO (1) CO5170416A1 (es)
CZ (1) CZ2001850A3 (es)
DE (1) DE69928945T2 (es)
EA (1) EA200100203A1 (es)
EE (1) EE200100145A (es)
ES (1) ES2252960T3 (es)
GE (1) GEP20033025B (es)
GT (1) GT199900146A (es)
HK (1) HK1040396A1 (es)
HN (1) HN1999000149A (es)
HR (1) HRP20010167A2 (es)
HU (1) HUP0103542A3 (es)
ID (1) ID29129A (es)
IL (1) IL141506A0 (es)
IS (1) IS5860A (es)
MA (1) MA26686A1 (es)
NO (1) NO20011183L (es)
NZ (1) NZ509841A (es)
OA (1) OA11648A (es)
PA (1) PA8481301A1 (es)
PE (1) PE20001053A1 (es)
PL (1) PL346648A1 (es)
SK (1) SK3032001A3 (es)
SV (1) SV1999000147A (es)
TN (1) TNSN99169A1 (es)
TR (1) TR200100694T2 (es)
WO (1) WO2000014066A1 (es)
YU (1) YU11501A (es)
ZA (1) ZA200101744B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP1038872A1 (en) 1999-02-22 2000-09-27 Pfizer Products Inc. 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands
SE9902765D0 (sv) * 1999-07-21 1999-07-21 Astra Pharma Prod Novel compounds
US6974824B2 (en) * 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
EP1279666A1 (en) * 2001-07-24 2003-01-29 Pfizer Products Inc. 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands
MXPA04007719A (es) 2002-02-07 2005-09-08 Univ Missouri Compuestos 4-(3hidroxifenil) o 4-(3-alcoxifenil)-1,2,4-triazol activos del receptor opioide.
SE0203301D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
ES2321509T3 (es) 2002-11-26 2009-06-08 Pfizer Products Inc. Compuestos de piperidina sustituidos con fenilo para usar como activadores de ppar.
WO2004091623A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals. Inc. Pharmaceutical formulations containing methylnaltrexone
AR044010A1 (es) * 2003-04-11 2005-08-24 Janssen Pharmaceutica Nv Uso de derivados de 4-fenil-4- [1h-imidazol-2-il]- piperidina sustituidos como agonistas delta opioideos no peptidos selectivos, con actividad antidepresiva y ansiolitica
US20070078120A1 (en) * 2003-10-21 2007-04-05 Hitoshi Ban Novel piperidine derivative
PL1706385T3 (pl) 2003-12-23 2011-03-31 Astex Therapeutics Ltd Pochodne pirazolu jako modulatory kinazy białkowej
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
US7872023B2 (en) * 2005-02-17 2011-01-18 Research Triangle Institute Kappa opioid receptor ligands
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
WO2006136823A1 (en) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
EP1902032A1 (en) 2005-06-22 2008-03-26 Astex Therapeutics Limited Pharmaceutical compounds
EP1933832A2 (en) 2005-06-23 2008-06-25 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
DE102005061427A1 (de) * 2005-12-22 2007-06-28 Grünenthal GmbH Substituierte Oxadiazol-Derivate
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
AU2008233129B2 (en) * 2007-03-29 2014-03-20 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
SI2565195T1 (sl) 2007-03-29 2015-09-30 Wyeth Llc Periferalni opioidni receptorji in antagonisti in njih uporaba
MX2009010550A (es) * 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
KR101581480B1 (ko) * 2008-02-06 2015-12-30 프로제닉스 파머슈티컬스, 인코포레이티드 (r),(r)-2,2'-비스-메틸날트렉손의 제조법 및 용도
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (en) * 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
EP2263664A1 (en) * 2009-05-18 2010-12-22 Nestec S.A. Opioid receptors stimulating compounds (thymoquinone, Nigella sativa) and food allergy
CA3050515A1 (en) 2017-01-17 2018-07-26 Mebias Discovery, Inc. Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same
US11584765B2 (en) 2017-03-12 2023-02-21 Ecstasy LLC Polycyclic amines as sigma receptor modulators
BR112019018774A2 (pt) * 2017-03-12 2020-04-07 Wang Xiaodong composto tendo uma estrutura de acordo com a fórmula i, sal farmaceuticamente aceitável, composição farmacêutica, método para prevenir ou tratar uma doença ou afeção e método para imunomodulação, inibição ou prevenção de rejeição de enxertos de órgãos ou pele ou tratamento de tumores ou câncer
US20190110804A1 (en) * 2017-10-16 2019-04-18 Michael Bruce Horowitz Catheter based retrieval device with proximal body having axial freedom of movement
JP2023532919A (ja) 2020-07-01 2023-08-01 エクスタシー・リミテッド・ライアビリティ・カンパニー オピオイド受容体変調のための多環式アミン

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1936452C3 (de) * 1969-07-17 1975-06-19 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenylpiperidlnen
US4016280A (en) 1969-07-17 1977-04-05 Byk Gulden Lomberg Chemische Fabrik Gmbh 4,4-Diarylpiperidine compositions and use
DE2166997C3 (de) 1971-08-04 1980-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen
DE2139084C3 (de) 1971-08-04 1979-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen
DE2139085C3 (de) * 1971-08-04 1979-01-18 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Halogenierte 4,4-Diphenyl-piperidine, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
ES2066721B1 (es) * 1993-05-18 1996-02-16 Ferrer Int Nuevos compuestos derivados de la piridina 1,4-disustituida.
US5434171A (en) * 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
US5994369A (en) * 1995-04-05 1999-11-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituted piperidine or pyrrolidine compounds for treating sigma-receptor modulated disorders
AU727972B2 (en) 1996-05-16 2001-01-04 H. Lundbeck A/S Dihydropyrimidines and uses thereof
EP0918767A4 (en) 1996-05-31 2000-04-26 Allelix Neuroscience Inc PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS

Also Published As

Publication number Publication date
AU749096B2 (en) 2002-06-20
EP1112255B1 (en) 2005-12-14
HUP0103542A3 (en) 2002-11-28
JP2002524445A (ja) 2002-08-06
KR20010075024A (ko) 2001-08-09
HRP20010167A2 (en) 2002-02-28
HK1040396A1 (zh) 2002-06-07
PA8481301A1 (es) 2000-09-29
EE200100145A (et) 2002-06-17
CA2343236A1 (en) 2000-03-16
PL346648A1 (en) 2002-02-25
HUP0103542A2 (hu) 2002-01-28
DE69928945D1 (de) 2006-01-19
NO20011183L (no) 2001-05-04
US20040138220A1 (en) 2004-07-15
EA200100203A1 (ru) 2001-08-27
MA26686A1 (fr) 2004-12-20
IL141506A0 (en) 2002-03-10
AP2001002088A0 (en) 2001-03-31
DE69928945T2 (de) 2006-07-27
ES2252960T3 (es) 2006-05-16
SV1999000147A (es) 2000-09-06
WO2000014066A1 (en) 2000-03-16
CA2343236C (en) 2006-01-03
IS5860A (is) 2001-02-23
CZ2001850A3 (cs) 2001-12-12
TR200100694T2 (tr) 2001-10-22
GEP20033025B (en) 2003-07-25
HN1999000149A (es) 2000-01-12
BR9913512A (pt) 2001-06-05
ATE312819T1 (de) 2005-12-15
PE20001053A1 (es) 2000-10-14
AR022376A1 (es) 2002-09-04
AU5383799A (en) 2000-03-27
CO5170416A1 (es) 2002-06-27
BG105411A (bg) 2001-12-29
YU11501A (sh) 2003-10-31
ID29129A (id) 2001-08-02
CN1316993A (zh) 2001-10-10
US6720336B2 (en) 2004-04-13
US20020013321A1 (en) 2002-01-31
NO20011183D0 (no) 2001-03-08
EP1112255A1 (en) 2001-07-04
SK3032001A3 (en) 2002-04-04
GT199900146A (es) 2001-02-24
ZA200101744B (en) 2002-06-03
TNSN99169A1 (fr) 2005-11-10
NZ509841A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
OA11648A (en) 4,4-Biarylpiperidine derivatives with opioid receptor activity.
AU760874B2 (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
WO2004013100A2 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
CA2546264A1 (en) 4-phenylpiperidine derivatives as renin inhibitors
US20040254190A1 (en) 3-Benzhydrylidene-8-aza-bicyclo[3.2.1]octane derivatives with opioid receptor activity
CA2299036C (en) 4-phenyl-4-heteroarylpiperidine derivatives
US6960609B2 (en) 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands
MXPA01002485A (es) Derivados de 4,4-biarilpiperidina
MXPA00001828A (es) Derivados de 4-fenil-4-heteroarilpiperidina
MXPA01006789A (es) Derivados de 3,3-biarilpiperidina y 2,2 -biarilmorfolina